Prelims
Bundibugyo Ebola Virus Outbreak
Context: A catastrophic outbreak of the rare Bundibugyo strain of Ebola originating in the Democratic Republic of Congo’s eastern Ituri province crossed the grim milestone of 10,000 confirmed cases and nearly 5,000 deaths.
About Bundibugyo Ebola Virus Outbreak:
What it is?
- A severe, acute, and often fatal viral haemorrhagic fever in humans and non-human primates, caused by viruses belonging to the genus Orthoebolavirus within the family Filoviridae. The average case fatality rate is roughly 50%, historically ranging between 25% and 90% depending on the viral species and outbreak response.
Origin:
- First identified simultaneously in 1976 during two independent outbreaks in Nzara (present-day South Sudan) and Yambuku (Democratic Republic of Congo), taking its name from the nearby Ebola River.
- Fruit bats belonging to the Pteropodidae family are considered the natural zoonotic reservoir hosts.
Key Features of Ebola:
- Direct-Contact Transmission: Spreads through direct contact with infected bodily fluids, contaminated materials or deceased patients. Unlike respiratory viruses, Ebola does not spread through routine airborne transmission.
- Symptom-Based Contagiousness: The incubation period ranges from 2–21 days, during which patients are not contagious. Transmission begins after symptoms appear and increases as the disease progresses.
- Clinical Manifestations: Initially causes fever, fatigue, muscle pain and headache, followed by vomiting, diarrhoea and organ dysfunction. Severe cases may develop internal bleeding and multi-organ failure.
- Six Viral Species: Traditionally classified into Zaire, Sudan, Bundibugyo, Taï Forest, Reston and Bombali ebolaviruses. Their disease-causing potential varies, with Reston and Bombali not established as causes of human disease.
- Viral Persistence: Ebola can persist in semen, eyes and the central nervous system after recovery, creating risks of delayed transmission and requiring continued medical monitoring.
Treatment and Medical Interventions:
- Monoclonal Antibody Treatment: Inmazeb and Ebanga are approved antibody-based treatments specifically for Zaire ebolavirus disease, reducing mortality when administered early.
- Treatment Gaps: No approved strain-specific treatments exist for Sudan and Bundibugyo ebolaviruses. Management relies on supportive care and investigational therapies.
